O'PKANING INTERSTITSIAL SHIKASTLANISHI BO'LGAN BEMORLARDA YO'TALNING INTENSIVLIGI VA TEZ-TEZLIGINING PROGNOSTIK AHAMIYATINI BAHOLASH
##article.subject##:
nospesifik interstitsial pnevmoniya, COVID-19, yo'tal chastotasi, yo'tal intensivligi, interstitsial o'pka kasalligi, biriktiruvchi to'qimalarning tizimli kasalligi##article.abstract##
Interstitsial o'pka kasalligida (IO’K) yo'talning intensivligi va chastotasi noaniqligicha qolmoqda. Tadqiqot maqsadi. Nospesifik interstitsial pnevmoniya (NsIP), tizimli biriktiruvchi to'qima kasalliklarida (IIP-TBTK) va COVID-19 bilan bog'liq interstitsial pnevmoniya (COVID-19AIP)dagi yo'talning intensivligi va chastotasini baholash va ularning klinik ko'rsatkichlar bilan bog'liqligini o'rganish. Materiallar va tadqiqot usullari. Ushbu tadqiqotda yo'talning intensivligi va chastotasi yo'talni sub'ektiv sifatli baholash (yo'tal yoki yo'tal yo'q), miqdoriy usullar, jumladan Listner yo'tal so'rovi (LCQ-Lester yo'tal so'rovi), vizual analog yo'tal shkalasi (VAS), yo'talning kunlik zo'ravonlik kundaligi va CQLQ-yo'talga xos hayot sifati so'rovnomasi, shuningdek, surunkali nafas qisilishi shkalasi va chastota shkalasi. gastroezofagial reflyuks kasalligida (GERK) yo'tal. Yo'talning intensivligi va chastotasi o'rtasidagi potentsial bashorat qiluvchi o'zgaruvchilar bilan bog'liqlik ikki o'zgaruvchan va ko'p logistik regressiya tahlillari yordamida sinovdan o'tkazildi. Natijalar. Tadqiqotga quyidagilar kiradi: NSIP bilan kasallangan 200 bemor, mos ravishda IIP-TBTK va COVID-19AIP-59 bilan kasallangan 49 bemor. NSIP va COVID-19AIP bilan og'rigan bemorlar tadqiqot guruhlari orasida yo'talning eng yuqori intensivligiga ega edi. NSIP va COVID-19 AIP bo'lgan bemorlarda yo'talning intensivligi va chastotasi o'pka diffuziyasi bilan salbiy bog'liq edi. IIP-TBTK da yo'talning intensivligi va chastotasi yuqori FSSG ko'rsatkichi bilan bog'liq edi (GERD belgilari uchun chastota shkalasi). IIP-TBTK bilan og'rigan bemorlarning ko'p qirrali tahlilida FSSG ko'rsatkichi mustaqil va ikkala yo'tal komponenti bilan bog'liq edi. Nihoyat, biz bemorlarning har uch guruhida yo'talning intensivligi va chastotasi o'rtasidagi farqlarning xususiyatlarini ko'rib chiqdik. Yo'talning chastotasi va intensivligi klinik belgilarning qolgan qismidan ustun bo'lgan bemorlarda boshqa bemorlarga nisbatan salomatlik ko'rsatkichlari (CQLQ yo'talining hayot sifati so'rovi) sezilarli darajada yomonlashgan. Topilmalar. Yo'talning intensivligi IIP-TBTK bilan solishtirganda NSIP va COVID-19AIP bilan yuqori edi. IIP-TBTK ning pastki turiga qarab yo'talning intensivligi va chastotasi bilan bog'liq bo'lgan turli xil klinik ko'rsatkichlar. Yo'talning chastotasi yo'tal intensivligi bilan solishtirganda sub'ektiv salomatlik holati bilan kuchli bog'liq edi. Yo'talning intensivligi va chastotasini baholashda biz tomonidan olingan ma'lumotlar yo'tal bilan bog'liq ob'ektiv va sub'ektiv omillarni hisobga olgan holda bemorlarni boshqarish zarurligini ko'rsatadi.
Библиографические ссылки
Ryerson CJ, Abbritti M, Ley B, Elicker BM, Jones KD, Collard HR. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology. 2011;16: 969–75.
Theodore AC, Tseng CH, Li N, Elashoff RM, Tashkin DP. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the scleroderma lung study. Chest. 2012;142:614–21.
Cheng JZ, Wilcox PG, Glaspole I, Corte TJ, Murphy D, Hague CJ, et al. Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases. Respirology. 2017;22:1592–7.
Raj AA, Birring SS. Clinical assessment of chronic cough severity. Pulm Pharmacol Ther. 2007;20:334–7.
Morice AH, Fontana GA, Belvisi MG, Birring SS, Chung KF, Dicpinigaitis PV, et al. ERS guidelines on the assessment of cough. Eur Respir J. 2007;29:1256–76.
Key AL, Holt K, Hamilton A, Smith JA, Earis JE. Objective cough frequency in idiopathic pulmonary fibrosis. Cough. 2010;6:4.
van Manen MJ, Birring SS, Vancheri C, Cottin V, Renzoni EA, Russell AM, et al. Cough in idiopathic pulmonary fibrosis. Eur Respir Rev. 2016;25:278–86.
Garner J, George PM, Renzoni E. Cough in interstitial lung disease. Pulm Pharmacol Ther. 2015;35:122–8.
Tashkin DP, Volkmann ER, Tseng CH, Roth MD, Khanna D, Furst DE, et al. Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease: results of scleroderma lung study II. Chest. 2017;151:813–20.
Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167:962–9.
Leslie KO. Idiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the aging lung: a unifying hypothesis regarding etiology and pathogenesis. Arch Pathol Lab Med. 2012;136:591– 600.
Harrison NK. Idiopathic pulmonary fibrosis: a nervous cough? Pulm Pharmacol Ther. 2004;17:347–50.
Savarino E, Bazzica M, Zentilin P, Pohl D, Parodi A, Cittadini G, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma. Am J Respir Crit Care Med. 2009;179:408–13.
Chung KF, Pavord ID. Chronic cough 1 - prevalence, pathogenesis, and causes of chronic cough. Lancet. 2008;371:1364–74.
Tobin RW, Pope CE 2nd, Pellegrini CA, Emond MJ, Sillery J, Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158:1804–8.
Каримова М. М. и др. СOVID-19 O’TKAZGAN BEMORLARDA QALQONSIMON BEZ XOLATINI TAXLIL QILISH //Журнал кардиореспираторных исследований. – 2022. – Т. 3. – №. 1.
Abdurashidovna A. Z. COVID-19 YURAK QON TOMIR KASALLIKLARI BOR BEMORLARDA KECHISHI //Журнал кардиореспираторных исследований. – 2021. – Т. 2. – №. 2.
Тогаева Б. и др. COVID-19 YURAK QON TOMIR KASALLIKLARI BOR BEMORLARDA KECHISHI //Журнал кардиореспираторных исследований. – 2021. – Т. 2. – №. 2. – С. 47-50.
